Acetylation of lysine is an important reversible modification. The activities of some proteins are controlled by acetylation of lysine. Histone acetyltransferases (HATs) acetylate the conserved amino-terminal domains of the four core histones (H2A, H2B, H3 and H4) that contain lysine residues. Histone deacetylases (HDACs) remove the acetyl group from the same residue. Acetylation/deacetylation of histones results in cell signaling processes that include gene activity, cell growth, differentiation and apoptosis. In cancer and polyglutamine diseases, the regulation of protein acetylation/deacetylation is impaired. Numerous anti-cancer drugs target HDACs.

This antibody is an affinity purified rabbit polyclonal that recognizes the acetylated form of lysine.KLH-acetylated lysine is used as the antigen, and the antibody is affinity purified using immobilized acetylated lysine.The affinity purified antibody is conjugated to FITC (fluorescein isothiocyanate). The concentration is 250 åµg/ml.

Reported to be effective for direct immunofluorescence experiments.

To view protocol(s) for this and other products please visit: www.ATSbio.com/support/protocols

Advanced Targeting Systems(ATS)位于美国加州圣地亚哥， 成立于1994年。 公司发起人Douglas Lappi和Ronald Wiley博士在实验室开发出先进的分子神经外科学研究技术。ATS主要生产用于科研和药物研发的靶向试剂，公司在疼痛和药物转运的研究及临床治疗的两个产品已获专利保护。目前，产品包括靶向毒素 (可提供基底前脑胆碱能神经元、去甲肾上腺素能和肾上腺素能神经元、巨噬细胞和小胶质细胞的特异性损伤试剂等)、二抗生物素、神经元抗体、神经递质抗体、蛋白质和荧光结合物、免疫毒素对照等。